X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ABBOTT INDIA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ABBOTT INDIA BIOCON LTD/
ABBOTT INDIA
 
P/E (TTM) x 92.4 40.2 229.9% View Chart
P/BV x 7.8 10.3 75.8% View Chart
Dividend Yield % 0.1 0.7 22.1%  

Financials

 BIOCON LTD   ABBOTT INDIA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
ABBOTT INDIA
Mar-18
BIOCON LTD/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,1886,110 19.4%   
Low Rs3053,996 7.6%   
Sales per share (Unadj.) Rs68.71,552.2 4.4%  
Earnings per share (Unadj.) Rs7.6188.8 4.0%  
Cash flow per share (Unadj.) Rs14.0196.4 7.1%  
Dividends per share (Unadj.) Rs1.0055.00 1.8%  
Dividend yield (eoy) %0.11.1 12.3%  
Book value per share (Unadj.) Rs86.3796.6 10.8%  
Shares outstanding (eoy) m600.0021.25 2,823.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.3 333.7%   
Avg P/E ratio x98.926.8 369.4%  
P/CF ratio (eoy) x53.425.7 207.7%  
Price / Book Value ratio x8.66.3 136.3%  
Dividend payout %13.229.1 45.5%   
Avg Mkt Cap Rs m447,900107,376 417.1%   
No. of employees `0006.13.3 185.1%   
Total wages/salary Rs m9,3113,937 236.5%   
Avg. sales/employee Rs Th6,705.89,929.3 67.5%   
Avg. wages/employee Rs Th1,514.21,185.1 127.8%   
Avg. net profit/employee Rs Th736.91,207.7 61.0%   
INCOME DATA
Net Sales Rs m41,23432,985 125.0%  
Other income Rs m2,0621,170 176.3%   
Total revenues Rs m43,29634,155 126.8%   
Gross profit Rs m8,2915,245 158.1%  
Depreciation Rs m3,851162 2,378.6%   
Interest Rs m61538 1,609.9%   
Profit before tax Rs m5,8876,215 94.7%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5692,203 71.2%   
Profit after tax Rs m4,5314,012 112.9%  
Gross profit margin %20.115.9 126.5%  
Effective tax rate %26.735.4 75.2%   
Net profit margin %11.012.2 90.3%  
BALANCE SHEET DATA
Current assets Rs m41,48622,655 183.1%   
Current liabilities Rs m21,4136,681 320.5%   
Net working cap to sales %48.748.4 100.5%  
Current ratio x1.93.4 57.1%  
Inventory Days Days6465 98.7%  
Debtors Days Days9429 323.1%  
Net fixed assets Rs m50,661835 6,063.8%   
Share capital Rs m3,000213 1,411.8%   
"Free" reserves Rs m48,80816,715 292.0%   
Net worth Rs m51,80816,928 306.1%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89724,162 413.4%  
Interest coverage x10.6163.7 6.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.41.4 30.2%   
Return on assets %5.216.8 30.7%  
Return on equity %8.723.7 36.9%  
Return on capital %9.636.9 26.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,058369 3,271.8%   
Fx outflow Rs m7,3483,807 193.0%   
Net fx Rs m4,710-3,438 -137.0%   
CASH FLOW
From Operations Rs m6,6211,527 433.6%  
From Investments Rs m-6,840-2,148 318.4%  
From Financial Activity Rs m-2,397-1,024 234.0%  
Net Cashflow Rs m-2,612-1,646 158.7%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 7.9 106.3%  
FIIs % 10.7 0.1 10,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.1 116.4%  
Shareholders   109,995 18,270 602.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS